Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

Rhea-AI Summary

Aptose Biosciences announced that its Chairman and CEO, William G. Rice, Ph.D., will present at the Biotech Showcase™ 2023 Conference on January 10, 2023, at 10:00 a.m. PST in San Francisco. The company specializes in developing oral kinase inhibitors for hematologic malignancies, with two clinical-stage products: tuspetinib for acute myeloid leukemia and luxeptinib for other hematologic conditions. Additionally, Aptose will hold meetings at the LifeSci Advisors Corporate Access Event from January 9-11, 2023. The presentation will be available via webcast on the company’s website.

SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10^th, 2023, at 10:00 a.m. PST in San Francisco, CA.

Conference Presentation Details:

Date:		Tuesday, January 10, 2023
Time:		10:00 a.m. PST
Location:		Track Yosemite - C (Ballroom Level)
		Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
Webcast:		LINK

The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com.

The Company also will be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco on January 9-11, 2023. To schedule a meeting with Aptose, investors can request a meeting on the online system here.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (formerly HM43239), an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.		LifeSci Advisors, LLC
Susan Pietropaolo		Dan Ferry, Managing Director
Investor Relations		617-535-7746
201-923-2049		Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

 

FAQ

What is Aptose's participation in the Biotech Showcase 2023 conference?

Aptose will participate in the Biotech Showcase 2023 conference on January 10, 2023, at 10:00 a.m. PST.

Who is presenting for Aptose at the conference?

William G. Rice, Ph.D., the Chairman and CEO, will present at the conference.

What products is Aptose developing for hematologic malignancies?

Aptose is developing tuspetinib and luxeptinib as oral kinase inhibitors for hematologic malignancies.

When will the audio webcast of the conference presentation be available?

The audio webcast will be archived shortly after the live event and available on Aptose's website.

What other events is Aptose participating in during January 2023?

Aptose will hold meetings at the LifeSci Advisors Corporate Access Event from January 9-11, 2023.